CellaVision AB (CEVI)

Sell: 203.00 SEK|Buy: 204.00 SEK|Change: 4.40 (2.23%)

Open 

203.00 SEK


Previous close 

197.60 SEK


Trade high 

203.50 SEK


Volume 

89,039


Year high 

302.00 SEK


Year low 

147.80 SEK


Dividend yield 

1.14%


Market capitalisation 

4.82 bn SEK


P/E ratio 

33.49


ISIN 

SE0000683484


Share price

Performance 30/04/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
CellaVision AB+ 2.23
More...

Company profile

CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers or software.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.